Form 4: BIO-KEY CFO Granted 35,000 Restricted Shares

BIO-KEY International's Chief Financial Officer, Cecilia C. Welch, was granted 35,000 shares of restricted common stock under the company's 2023 Stock Incentive Plan.

Summary

• Cecilia C. Welch, Chief Financial Officer of BIO-KEY INTERNATIONAL, INC., was granted 35,000 shares of common stock.
• The transaction date for this grant is reported as September 2, 2025.
• The shares were acquired at a price of $0, indicating a grant rather than a purchase.
• These are Restricted Stock units granted under the Issuer's 2023 Stock Incentive Plan, as amended.
• The restricted stock will vest in three equal annual installments on each of the next three anniversaries of the grant date.
• Vesting is contingent upon Ms. Welch's continued employment with or service to the Issuer through the applicable vesting date.
• Following this transaction, Ms. Welch beneficially owns 59,396 shares of common stock.
• The reported holdings do not include options to purchase an additional 174 shares.

Sentiment

Score: 7

Explanation: The grant of restricted stock to the CFO is a positive step in aligning executive incentives with shareholder interests, promoting long-term commitment and performance. While not a direct cash investment by the insider, it signals continued executive engagement.

Positives

• The grant of restricted stock aligns the Chief Financial Officer's interests with long-term shareholder value, incentivizing sustained performance.
• Equity compensation is a standard practice that helps retain key executives and motivates them to contribute to the company's growth.

Negatives

• The transaction represents a grant of shares at a $0 price, not a direct cash investment by the insider, which would signal stronger personal conviction.

Risks

• The vesting of the restricted stock is subject to the Reporting Person's continued employment or service to the Issuer, posing a risk of forfeiture if employment ceases.

Future Outlook

The grant of restricted stock with a three-year vesting schedule indicates a commitment to retaining the Chief Financial Officer and aligning her incentives with the company's long-term performance and strategic objectives.

Industry Context

The grant of restricted stock to a key executive like the CFO is a common and widely accepted practice in the technology and broader corporate sectors for executive compensation. It serves to attract, retain, and motivate top talent by linking their personal wealth to the company's stock performance over time.

Comparison to Industry Standards

• The use of restricted stock as a component of executive compensation is a standard practice across industries, comparable to equity incentive plans at companies like Microsoft, Apple, or Google, which frequently use stock grants to align executive interests with shareholder returns.
• The three-year vesting schedule is a typical duration for such grants, providing a balance between immediate incentive and long-term retention, similar to practices observed in many publicly traded technology companies.

Corporate Governance

Related Party Transactions

• The grant of 35,000 shares of restricted common stock to Cecilia C. Welch, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of management's financial interests with the company's long-term performance and stock appreciation.
• Employees (CFO): Receives equity compensation, providing a significant incentive for continued service and performance, contributing to personal wealth accumulation tied to company success.

Next Steps

• The restricted stock will vest in three equal annual installments on the next three anniversaries of the grant date (September 2, 2025), subject to continued employment.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to an executive as part of their compensation package, which is generally seen as a positive for aligning management incentives. However, it does not provide new fundamental information or a significant change in the company's operational or financial outlook to warrant a change in investment recommendation based solely on this filing.

Keywords

BIO-KEY International, BKYI, Cecilia C. Welch, Chief Financial Officer, Restricted Stock, Stock Grant, Insider Transaction, Form 4, Equity Compensation, 2023 Stock Incentive Plan